Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastoma.

Tee, Andrew E; Ciampa, Olivia C; Wong, Matthew; Fletcher, Jamie I; Kamili, Alvin; Chen, Jingwei; Ho, Nicholas; Sun, Yuting; Carter, Daniel R; Cheung, Belamy B; Marshall, Glenn M; Liu, Pei Y; Liu, Tao

Tee, Andrew E; Ciampa, Olivia C; Wong, Matthew; Fletcher, Jamie I; Kamili, Alvin; Chen, Jingwei; Ho, Nicholas; Sun, Yuting; Carter, Daniel R; Cheung, Belamy B; Marshall, Glenn M; Liu, Pei Y; Liu, Tao.

Afiliación

Tee AE; Children's Cancer Institute Australia for Medical Research, Randwick, New South Wales, Australia.
Ciampa OC; Children's Cancer Institute Australia for Medical Research, Randwick, New South Wales, Australia.
Wong M; Children's Cancer Institute Australia for Medical Research, Randwick, New South Wales, Australia.
Fletcher JI; Children's Cancer Institute Australia for Medical Research, Randwick, New South Wales, Australia.
Kamili A; Children's Cancer Institute Australia for Medical Research, Randwick, New South Wales, Australia.
Chen J; Children's Cancer Institute Australia for Medical Research, Randwick, New South Wales, Australia.
Ho N; Children's Cancer Institute Australia for Medical Research, Randwick, New South Wales, Australia.
Sun Y; Children's Cancer Institute Australia for Medical Research, Randwick, New South Wales, Australia.
Carter DR; Children's Cancer Institute Australia for Medical Research, Randwick, New South Wales, Australia.
Cheung BB; Children's Cancer Institute Australia for Medical Research, Randwick, New South Wales, Australia.
Marshall GM; School of Women's and Children's Health, UNSW Sydney, Randwick, New South Wales, Australia.
Liu PY; Children's Cancer Institute Australia for Medical Research, Randwick, New South Wales, Australia.
Liu T; Kids Cancer Centre, Sydney Children's Hospital, Randwick, New South Wales, Australia.

Int J Cancer ; 147(7): 1928-1938, 2020 10 01.

Article en En | MEDLINE | ID: mdl-32086952

Asunto(s)

Proteína Proto-Oncogénica N-Myc/genética; Neuroblastoma/genética; Fenilendiaminas/farmacología; Inhibidores de Proteínas Quinasas/farmacología; Pirimidinas/farmacología; Línea Celular Tumoral; Proliferación Celular/efectos de los fármacos; Supervivencia Celular/efectos de los fármacos; Quinasas Ciclina-Dependientes/antagonistas & inhibidores; Proteínas de Unión al ADN/genética; Proteínas de Unión al ADN/metabolismo; Regulación hacia Abajo; Sinergismo Farmacológico; Amplificación de Genes; Regulación Neoplásica de la Expresión Génica/efectos de los fármacos; Humanos; Imidazoles/farmacología; Lapatinib/farmacología; Neuroblastoma/tratamiento farmacológico; Neuroblastoma/metabolismo; Piridazinas/farmacología; Proteínas de Unión al ARN/genética; Proteínas de Unión al ARN/metabolismo; Quinasa Activadora de Quinasas Ciclina-Dependientes

Palabras clave

CDK7; N-Myc; PNUTS; THZ1; neuroblastoma; tyrosine kinase inhibitors

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Fenilendiaminas / Pirimidinas / Inhibidores de Proteínas Quinasas / Proteína Proto-Oncogénica N-Myc / Neuroblastoma Límite: Humans Idioma: En Año: 2020 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google